JP2023518419A - ブレキナルナトリウムの安定した多形性組成物ならびにその使用および製造方法 - Google Patents

ブレキナルナトリウムの安定した多形性組成物ならびにその使用および製造方法 Download PDF

Info

Publication number
JP2023518419A
JP2023518419A JP2022556043A JP2022556043A JP2023518419A JP 2023518419 A JP2023518419 A JP 2023518419A JP 2022556043 A JP2022556043 A JP 2022556043A JP 2022556043 A JP2022556043 A JP 2022556043A JP 2023518419 A JP2023518419 A JP 2023518419A
Authority
JP
Japan
Prior art keywords
hours
sodium salt
cancer
brequinal
polymorphic form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022556043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518419A5 (enExample
Inventor
アブドルサマド タダヨン，
ピン フアン，
チャオイー デン，
ジンスオ ヤン，
シーイー ジアン，
チンチン ルー，
リン ツイ，
モ ジア，
シャンジュン ヨウ，
デイビッド ピー． ヘッソン，
Original Assignee
クリア クリーク バイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリア クリーク バイオ， インコーポレイテッド filed Critical クリア クリーク バイオ， インコーポレイテッド
Publication of JP2023518419A publication Critical patent/JP2023518419A/ja
Publication of JP2023518419A5 publication Critical patent/JP2023518419A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022556043A 2020-03-20 2021-03-19 ブレキナルナトリウムの安定した多形性組成物ならびにその使用および製造方法 Pending JP2023518419A (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202062992720P 2020-03-20 2020-03-20
US62/992,720 2020-03-20
US202063020460P 2020-05-05 2020-05-05
US63/020,460 2020-05-05
US202063030677P 2020-05-27 2020-05-27
US63/030,677 2020-05-27
US202063043382P 2020-06-24 2020-06-24
US202063043386P 2020-06-24 2020-06-24
US202063043388P 2020-06-24 2020-06-24
US202063043384P 2020-06-24 2020-06-24
US63/043,384 2020-06-24
US63/043,388 2020-06-24
US63/043,386 2020-06-24
US63/043,382 2020-06-24
PCT/US2021/023350 WO2021189017A1 (en) 2020-03-20 2021-03-19 Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof

Publications (2)

Publication Number Publication Date
JP2023518419A true JP2023518419A (ja) 2023-05-01
JP2023518419A5 JP2023518419A5 (enExample) 2024-03-28

Family

ID=77771654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022556043A Pending JP2023518419A (ja) 2020-03-20 2021-03-19 ブレキナルナトリウムの安定した多形性組成物ならびにその使用および製造方法

Country Status (5)

Country Link
EP (1) EP4121050A4 (enExample)
JP (1) JP2023518419A (enExample)
AU (1) AU2021236757A1 (enExample)
CA (1) CA3175964A1 (enExample)
WO (1) WO2021189017A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159763A1 (en) * 2021-01-22 2022-07-28 Model Medicines, Inc. Sars-cov-2 therapeutics
WO2023043830A1 (en) * 2021-09-15 2023-03-23 Clear Creek Bio, Inc. Combination therapies to treat viral infections
CN120131690A (zh) * 2025-03-24 2025-06-13 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种布喹那在制备抑制流感病毒的制剂中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018529761A (ja) * 2015-09-01 2018-10-11 ザ・ブロード・インスティテュート・インコーポレイテッド 血液がんの治療または予防に有用な化合物および方法
WO2019191032A1 (en) * 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05011525A (es) * 2003-04-30 2005-12-12 Nippon Shinyaku Co Ltd Cristales de solvato de derivado de acido quinolincarboxilico.
CA2910112C (en) * 2013-04-25 2021-02-16 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
US20190290634A1 (en) * 2018-03-26 2019-09-26 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
WO2019246603A1 (en) * 2018-06-22 2019-12-26 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018529761A (ja) * 2015-09-01 2018-10-11 ザ・ブロード・インスティテュート・インコーポレイテッド 血液がんの治療または予防に有用な化合物および方法
WO2019191032A1 (en) * 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
YI-YU KE ET AL.: "Artificial intelligence approach fighting COVID-19 with repurposing drugs", BIOMEDICAL JOURNAL, vol. 43, JPN6025000065, 15 May 2020 (2020-05-15), pages 355 - 362, ISSN: 0005792856 *
川口洋子ら: "医薬品と結晶多形", 生活工学研究, vol. 4, no. 2, JPN6014015069, 2002, pages 310 - 317, ISSN: 0005792855 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014035600, 2008, pages 17 - 23, ISSN: 0005792854 *

Also Published As

Publication number Publication date
EP4121050A1 (en) 2023-01-25
CA3175964A1 (en) 2021-09-23
WO2021189017A1 (en) 2021-09-23
EP4121050A4 (en) 2024-04-17
AU2021236757A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
US12076315B2 (en) Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
TWI786110B (zh) (s)-2-乙基丁基2-(((s)-(((2r,3s,4r,5r) -5-(4-胺基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4-二羥基四氫呋喃-2-基)甲氧基)(苯氧基)磷醯基)胺基)丙酸酯之結晶形式
JP2023518419A (ja) ブレキナルナトリウムの安定した多形性組成物ならびにその使用および製造方法
BR112020000941A2 (pt) métodos de tratamento para fibrose cística
CA3210612C (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN107540710A (zh) 肝递送抗病毒前体药物核苷环磷酸酯化合物及应用
JPH09165336A (ja) 癌疾患治療におけるイソオキサゾールおよびクロトンアミド誘導体の使用
CN112912075B (zh) 治疗前列腺癌的组合疗法
CN105820130B (zh) 三氮唑正丙酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
WO2022226312A1 (en) Combination nucleotide pool depletion for treatment of viral infections and cancers
TWI769395B (zh) 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑
WO2020123241A1 (en) Multiphasic dosing regimens for treating cancer
EP3845537B1 (en) Crystal of pyrazolo[3,4-d]pyrimidine
HK40053354A (en) Combination therapy for the treatment of prostate cancer
HK40053354B (en) Combination therapy for the treatment of prostate cancer
CN115819349A (zh) 一种吡唑类化合物及其制备方法和应用
CN121085931A (zh) 一种巴瑞克替尼与糖精共晶及其制备方法
CN121085932A (zh) 一种巴瑞克替尼与4-羟基苯甲酸共晶及其制备方法
CN120837493A (zh) Fascin蛋白抑制剂在抑制病毒感染中的应用
CN113801101A (zh) Azd9291-2-酮戊二酸盐及其制备方法
CN121085927A (zh) 一种巴瑞克替尼草酸盐结晶形式及其制备方法
EA041961B1 (ru) Способы лечения муковисцидоза
CN112513003A (zh) 伊拉非诺盐
TW202000665A (zh) 含有吡啶酮之三環化合物的結晶型、其製備方法及其使用方法
EA044198B1 (ru) Комбинированная терапия для лечения рака предстательной железы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260210